HIGHLIGHTS
Quercis Pharma is a late clinical stage biotech startup with Phase III assets and strong IP extending through 2045.
Clinical progress
Phase 3 program for cancer thrombosis prevention under FDA Special Protocol Agreement.
Multiple Assets
Cancer-associated thrombosis, Sickle Cell Disease, ALS, COPD, viral diseases.
Strong IP
Patent protection supported by DLA Piper.
Leadership
Our leadership team includes pioneers who have guided the approval of more than 50 therapies. Their collective expertise spans global regulatory strategy, drug development, and commercialization — giving Quercis a foundation few biotech companies can match.
Advisors
Quercis is advised by some of the world’s most accomplished scientists and clinicians, including leaders who have overseen the registration of 17 cancer drugs. With direct ties to Harvard, ETH Zurich, Cornell, and other top institutions, our team brings unmatched experience, credibility, and reach to advance our mission.
Global Mission
Committed to responsible pricing and universal access.
